<DOC>
	<DOCNO>NCT01358968</DOCNO>
	<brief_summary>The purpose study assess effect LY2603618 protein ( enzyme CYP2D6 ) involve metabolic pathway Desipramine patient cancer . This drug interaction study treatment disease main purpose study . The study involve two single dos 50mg , 1 tablet mouth , Day 1 Period 1 2 . In Period 1 Desipramine administer alone , In Period 2 Desipramine administer combination LY2603618 . LY2603618 administer 275mg IV infusion 1hr . Desipramine administered end LY2603618 infusion . Information side effect may occur also collect .</brief_summary>
	<brief_title>A Drug Interaction Study Assess Effect LY2603618 Metabolic Pathway Desipramine</brief_title>
	<detailed_description />
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Desipramine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Have histological cytological diagnosis cancer ( solid tumor ) , clinical radiologic evidence locally advance and/or metastatic disease , lifeprolonging therapy exists ( , refractory standard therapy and/or therapy know provide clinical benefit , standard therapy exists ) . Note : Patients progressive disease receive pemetrexed metastatic disease exclude receive combination pemetrexed safety extension study . Patients progressive disease receive gemcitabine metastatic disease exclude receive combination gemcitabine safety extension study . Have body surface area ( BSA ) great equal 1.37 m^2 Have give write informed consent prior studyspecific procedure Have adequate hematologic , hepatic renal function Have performance status less equal 2 Eastern Cooperative Oncology Group ( ECOG ) scale Have discontinue previous treatment cancer , include chemotherapy , radiotherapy , anticancer hormone therapy investigational therapy least 30 day prior study entry recover acute effect therapy ( least 42 day mitomycinC nitrosoureas , 60 day biologics ) Are reliable willing make available duration study willing follow study procedure Males female reproductive potential : Must agree use medically approve contraceptive precaution study least 3 month follow last dose study drug Females childbearing potential : Have negative serum pregnancy test less equal 7 day first dose study drug must also breastfeed Have estimate life expectancy , judgment investigator , permit patient complete 1 full cycle treatment beyond drug interaction portion study ( approximately 8 week ) Are able swallow tablet Prior radiation therapy treatment cancer allow &lt; 25 % bone marrow patient must recover acute toxic effect treatment prior study enrollment . Prior radiation whole pelvis allow . Prior radiotherapy must complete least 4 week study entry . Have receive treatment within 28 day initial dose study drug experimental agent noncancer indication receive regulatory approval indication Poor metabolizer ( PM ) status CYP2D6 ( genotyped ) Have previously complete withdrawn study study investigate LY2603618 checkpoint kinase one ( Chk1 ) inhibitor Have know allergy gemcitabine , pemetrexed , desipramine LY2603618 ingredient gemcitabine , pemetrexed , desipramine LY2603618 ( like CaptisolÂ® ) Have serious preexist medical condition ( leave discretion investigator ) advance cancer Have symptomatic central nervous system ( CNS ) malignancy metastasis ( screen require ) . Patients treat CNS metastasis eligible study currently receive corticosteroid and/or anticonvulsant , disease asymptomatic radiographically stable least 90 day . Have current hematologic malignancy either acute chronic leukemia Have active fungal , bacterial , and/or know viral infection include human immunodeficiency virus ( HIV ) viral ( A , B , C ) hepatitis ( screen require ) Have QTc interval &gt; 500 msec screen electrocardiogram ( ECG ) Have ECG abnormality screen ECG significant conduction abnormality , ischemic change ( prior Qwave myocardial infarction and/or mark ischemic ST Twave ) , arrhythmia ( persistent paroxysmal ventricular supraventricular arrhythmia , include atrial fibrillation ) , ECG abnormality would put patient unnecessary risk opinion investigator Drugs narrow therapeutic window also know substrate CYP2D6 drug classify sensitive substrate CYP2D6 exclude Drugs herbal supplement know inhibitor CYP2D6 exclude study , 30day period ( minimum 5 halflives , whichever less ) prior study start Patients average weekly alcohol intake exceed 21 unit per week ( male ) 14 unit per week ( female ) , patient unwilling stop alcohol consumption 24 hour study end study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>